Your browser doesn't support javascript.
loading
Pharmacokinetic Analysis of Peptide-Modified Nanoparticles with Engineered Physicochemical Properties in a Mouse Model of Traumatic Brain Injury.
Waggoner, Lauren E; Madias, Marianne I; Hurtado, Alan A; Kwon, Ester J.
Afiliación
  • Waggoner LE; Department of Nanoengineering, University of California San Diego, La Jolla , CA , USA.
  • Madias MI; Department of Bioengineering, University of California San Diego, La Jolla , USA, CA.
  • Hurtado AA; Department of Bioengineering, University of California San Diego, La Jolla , USA, CA.
  • Kwon EJ; Department of Bioengineering, University of California San Diego, La Jolla , USA, CA . ejkwon@ucsd.edu.
AAPS J ; 23(5): 100, 2021 08 16.
Article en En | MEDLINE | ID: mdl-34401968
ABSTRACT
Peptides are used to control the pharmacokinetic profiles of nanoparticles due to their ability to influence tissue accumulation and cellular interactions. However, beyond the study of specific peptides, there is a lack of understanding of how peptide physicochemical properties affect nanoparticle pharmacokinetics, particularly in the context of traumatic brain injury (TBI). We engineered nanoparticle surfaces with peptides that possess a range of physicochemical properties and evaluated their distribution after two routes of administration direct injection into a healthy mouse brain and systemic delivery in a mouse model of TBI. In both administration routes, we found that peptide-modified nanoparticle pharmacokinetics were influenced by the charge characteristics of the peptide. When peptide-modified nanoparticles are delivered directly into the brain, nanoparticles modified with positively charged peptides displayed restricted distribution from the injection site compared to nanoparticles modified with neutral, zwitterionic, or negatively charged peptides. After intravenous administration in a TBI mouse model, positively charged peptide-modified nanoparticles accumulated more in off-target organs, including the heart, lung, and kidneys, than zwitterionic, neutral, or negatively charged peptide-modified nanoparticles. The increase in off-target organ accumulation of positively charged peptide-modified nanoparticles was concomitant with a relative decrease in accumulation in the injured brain compared to zwitterionic, neutral, or negatively charged peptide-modified nanoparticles. Understanding how nanoparticle pharmacokinetics are influenced by the physicochemical properties of peptides presented on the nanoparticle surface is relevant to the development of nanoparticle-based TBI therapeutics and broadly applicable to nanotherapeutic design, including synthetic nanoparticles and viruses.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Barrera Hematoencefálica / Fármacos Neuroprotectores / Lesiones Traumáticas del Encéfalo / Sistema de Administración de Fármacos con Nanopartículas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: AAPS J Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Barrera Hematoencefálica / Fármacos Neuroprotectores / Lesiones Traumáticas del Encéfalo / Sistema de Administración de Fármacos con Nanopartículas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: AAPS J Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos